Table 3.
Comparison of different clinical and laboratory parameters between DOAC- (n = 26) and VKA-treated MPN patients (n = 45)
| Parameters | DOAC | VKA | p |
|---|---|---|---|
| Number of pts.* | 26 | 45 | |
| Median age at MPN diagnosis; years (range) | 55.5 (24.0–81.0) | 50.0 (22.0–82.0) | 0.131 |
| Median age at first ATE/VTE event; years (range) | 57.5 (27.0–88.0) | 53.0 (22.0–81.0) | 0.070 |
| Gender (male/female) | 8/18 | 14/31 | 0.976 |
| Essential thrombocythemia | 8 | 11 | 0.816 |
| Polycythemia vera | 10 | 20 | |
| Myelofibrosis | 7 | 13 | |
| JAK2 Mutation | 24 | 39 | 0.701 |
| Cardiovascular risk factors (yes/no) | 15/11 | 30/15 | 0.450 |
| ATE | 3 | 6 | 1.0 |
| VTE | 23 | 39 | |
| Median treatment time; years (range) | 1.3 (0.2–7.3) | 1.0 (0.1–20.4) | 0.984 |
| Median total follow up time; years (range) | 1.7 (0.2–7.3) | 4.8 (0.6–20.4) | 0.0005** |
| ATE/VTE recurrences | 4 | 22 | 0.0053** |
| Combined ASS use*** | 4 | 7 | 1.0 |
| Cytoreductive therapy for first ATE/VTE**** | 17 | 22 | 0.22 |
| Bleeding events total | 4 | 7 | 1.0 |
| Major bleeding events | 2 | 4 | 1.0 |
| Deaths | 1 | 3 | 1.0 |
*Pts. = patients
**Significantly different
***During time on anticoagulation after first ATE/VTE
****Begin at time of ATE/VTE or within 6 months thereafter